CLSA Increases SKB BIO-B's Target Price to HKD500.6, Maintains Outperform Rating
Company Performance: SKB BIO-B reported a 31.3% year-over-year decline in turnover for the first half of 2025, resulting in a net loss of RMB145 million, which was better than expected.
Analyst Rating Update: CLSA has increased its target price for SKB BIO-B from HKD328.4 to HKD500.6 and maintained an Outperform rating on the stock.
Sales Insights: The company's mid-term product sales reached RMB310 million, primarily driven by sac-TMT, with expectations for further growth due to label expansion for 2L NSCLC in the second half of 2025.
Market Data: As of August 19, 2025, SKB BIO-B had short selling valued at $30.61 million, with a ratio of 14.236%.
Trade with 70% Backtested Accuracy
Analyst Views on 06990
About the author
G Sachs: This Year, China's Healthcare Sector Depends More on Data and Earnings Clarity; Favorable Outlook for CDMO Companies
Healthcare Sector Outlook: Goldman Sachs predicts that the strong trend in China's healthcare sector will continue, with stock trading increasingly focused on companies' execution capabilities and R&D pipelines rather than just licensing expectations.
CDMO Companies Favorable: The broker is optimistic about CDMO companies due to their growth potential and reasonable valuations, upgrading WUXI APPTEC and WUXI XDC to Buy.
Selective Biotech and Pharma Strategy: Goldman Sachs favors biotech and pharmaceutical companies with promising data releases and transaction expectations, highlighting SKB BIO-B, HENLIUS, and HANSOH PHARMA as favorable investments.
Cautious on Medical Services: The broker maintains a neutral stance on the medical devices sector and is cautious about medical services due to cost control measures and weak consumption, downgrading HYGEIA HEALTH and JXR to Neutral/Sell.
Kelun-Biotech Showcases Drug R&D Achievements at JPMHC Conference
- Innovative Drug Development: Since initiating its innovation journey in 2012, Kelun-Biotech has rapidly emerged as a leader in China's innovative drug sector, leveraging its globally leading OptiDC™ platform to create a gradient portfolio for multiple tumor types, showcasing strong market competitiveness.
- Clinical Research Progress: The company has initiated nine pivotal studies targeting high-incidence tumor types in China, while multiple Phase II clinical studies for gynecological tumors are progressing steadily, further solidifying its leadership in cancer treatment.
- Commercialization Achievements: Kelun-Biotech's core products, sacituzumab tirumotecan and trastuzumab botidotin, have been approved for various indications in China, with the small-molecule RET inhibitor A400 expected to gain approval within the year, enhancing its product line and market share.
- Globalization Strategy: The company is actively expanding into overseas markets, establishing collaborations with international firms like MSD to maximize pipeline value, demonstrating its commitment and potential for global development.
JPM Identifies CN Healthcare Sector Decline as Buying Opportunity, Increases Price Targets for INNOVENT BIO and WUXI XDC
Market Overview: JPMorgan's report indicates that the Chinese healthcare sector has seen a retreat due to price negotiations and profit-taking, but the fundamentals remain strong, presenting a buying opportunity for 2026.
Stock Recommendations: The broker favors biotechnology and CXO sectors, highlighting top picks such as INNOVENT BIO, SKB BIO-B, WUXI APPTEC, and WUXI XDC, along with a positive outlook for MEDBOT-B in medical technology.
Target Price Adjustments: JPMorgan has adjusted target prices for several stocks, lowering AKESO's target from HKD166 to HKD149 while maintaining an Overweight rating, and slightly increasing INNOVENT BIO's target from HKD110 to HKD111.
Performance Metrics: The report includes short selling data for the highlighted stocks, indicating varying levels of short interest, with WUXI APPTEC and WUXI XDC showing significant short selling ratios.
CICC Publishes Portfolio of Trends in Hong Kong Stock Industry (Table)
Stock Performance Overview: TENCENT and BABA-W saw gains of 1.656% and 0.937% respectively, while XIAOMI-W, NTES-S, and SMIC experienced declines of 0.616%, 1.826%, and 3.181% respectively.
Short Selling Data: TENCENT had a short selling volume of $1.37B with a ratio of 16.234%, while NTES-S and BIDU-SW had higher short selling ratios of 37.112% and 37.529% respectively.
Analyst Expectations: Nomura predicts TENCENT's 3Q Non-IFRS net profit to grow by 12% year-over-year and has raised its target price to $757.
Additional Stock Movements: Other notable stocks include AKESO with a gain of 0.891% and SKB BIO-B with a decline of 2.200%, reflecting varied market performance.
CICC Reveals Top H-shares Picks for 2026 (Table)
CICC H-Share Outlook: CICC released its H-share outlook report for 2026, highlighting top stock picks including Tencent, Alibaba, and China Mobile, with varying short selling ratios.
Stock Performance: Notable stock movements include Tencent's increase of 1.656%, Alibaba's rise of 0.937%, and significant declines in stocks like Netease and SMIC.
Short Selling Data: The report includes short selling data, with Tencent and Alibaba having high short selling ratios of over 21%, indicating investor caution.
Market Trends: CLSA anticipates a 21% year-over-year growth in Tencent's adjusted EBIT for Q3, reflecting positive expectations for the company's performance.
<Research>HSBC Updates Ratings and Price Targets for Pharma and Biotech Stocks (Table)
Stock Ratings and Target Prices: BeOne Medicines Ltd. has a buy rating with a target price increase from US$323 to US$375, while several other companies like INNOVENT BIO and SKB BIO-B also received buy ratings with notable price increases.
Short Selling and Market Activity: Various stocks, including CSPC PHARMA and HENGRUI PHARMA, are experiencing significant short selling activity, with CSPC PHARMA being downgraded to neutral by UBS, indicating a shift in market sentiment.
G Sachs: This Year, China's Healthcare Sector Depends More on Data and Earnings Clarity; Favorable Outlook for CDMO Companies
Healthcare Sector Outlook: Goldman Sachs predicts that the strong trend in China's healthcare sector will continue, with stock trading increasingly focused on companies' execution capabilities and R&D pipelines rather than just licensing expectations.
CDMO Companies Favorable: The broker is optimistic about CDMO companies due to their growth potential and reasonable valuations, upgrading WUXI APPTEC and WUXI XDC to Buy.
Selective Biotech and Pharma Strategy: Goldman Sachs favors biotech and pharmaceutical companies with promising data releases and transaction expectations, highlighting SKB BIO-B, HENLIUS, and HANSOH PHARMA as favorable investments.
Cautious on Medical Services: The broker maintains a neutral stance on the medical devices sector and is cautious about medical services due to cost control measures and weak consumption, downgrading HYGEIA HEALTH and JXR to Neutral/Sell.
Kelun-Biotech Showcases Drug R&D Achievements at JPMHC Conference
- Innovative Drug Development: Since initiating its innovation journey in 2012, Kelun-Biotech has rapidly emerged as a leader in China's innovative drug sector, leveraging its globally leading OptiDC™ platform to create a gradient portfolio for multiple tumor types, showcasing strong market competitiveness.
- Clinical Research Progress: The company has initiated nine pivotal studies targeting high-incidence tumor types in China, while multiple Phase II clinical studies for gynecological tumors are progressing steadily, further solidifying its leadership in cancer treatment.
- Commercialization Achievements: Kelun-Biotech's core products, sacituzumab tirumotecan and trastuzumab botidotin, have been approved for various indications in China, with the small-molecule RET inhibitor A400 expected to gain approval within the year, enhancing its product line and market share.
- Globalization Strategy: The company is actively expanding into overseas markets, establishing collaborations with international firms like MSD to maximize pipeline value, demonstrating its commitment and potential for global development.
JPM Identifies CN Healthcare Sector Decline as Buying Opportunity, Increases Price Targets for INNOVENT BIO and WUXI XDC
Market Overview: JPMorgan's report indicates that the Chinese healthcare sector has seen a retreat due to price negotiations and profit-taking, but the fundamentals remain strong, presenting a buying opportunity for 2026.
Stock Recommendations: The broker favors biotechnology and CXO sectors, highlighting top picks such as INNOVENT BIO, SKB BIO-B, WUXI APPTEC, and WUXI XDC, along with a positive outlook for MEDBOT-B in medical technology.
Target Price Adjustments: JPMorgan has adjusted target prices for several stocks, lowering AKESO's target from HKD166 to HKD149 while maintaining an Overweight rating, and slightly increasing INNOVENT BIO's target from HKD110 to HKD111.
Performance Metrics: The report includes short selling data for the highlighted stocks, indicating varying levels of short interest, with WUXI APPTEC and WUXI XDC showing significant short selling ratios.
CICC Publishes Portfolio of Trends in Hong Kong Stock Industry (Table)
Stock Performance Overview: TENCENT and BABA-W saw gains of 1.656% and 0.937% respectively, while XIAOMI-W, NTES-S, and SMIC experienced declines of 0.616%, 1.826%, and 3.181% respectively.
Short Selling Data: TENCENT had a short selling volume of $1.37B with a ratio of 16.234%, while NTES-S and BIDU-SW had higher short selling ratios of 37.112% and 37.529% respectively.
Analyst Expectations: Nomura predicts TENCENT's 3Q Non-IFRS net profit to grow by 12% year-over-year and has raised its target price to $757.
Additional Stock Movements: Other notable stocks include AKESO with a gain of 0.891% and SKB BIO-B with a decline of 2.200%, reflecting varied market performance.
CICC Reveals Top H-shares Picks for 2026 (Table)
CICC H-Share Outlook: CICC released its H-share outlook report for 2026, highlighting top stock picks including Tencent, Alibaba, and China Mobile, with varying short selling ratios.
Stock Performance: Notable stock movements include Tencent's increase of 1.656%, Alibaba's rise of 0.937%, and significant declines in stocks like Netease and SMIC.
Short Selling Data: The report includes short selling data, with Tencent and Alibaba having high short selling ratios of over 21%, indicating investor caution.
Market Trends: CLSA anticipates a 21% year-over-year growth in Tencent's adjusted EBIT for Q3, reflecting positive expectations for the company's performance.
<Research>HSBC Updates Ratings and Price Targets for Pharma and Biotech Stocks (Table)
Stock Ratings and Target Prices: BeOne Medicines Ltd. has a buy rating with a target price increase from US$323 to US$375, while several other companies like INNOVENT BIO and SKB BIO-B also received buy ratings with notable price increases.
Short Selling and Market Activity: Various stocks, including CSPC PHARMA and HENGRUI PHARMA, are experiencing significant short selling activity, with CSPC PHARMA being downgraded to neutral by UBS, indicating a shift in market sentiment.
